Alba Therapeutics Corp.
This article was originally published in Start Up
Alba Therapeutics has identified the pathway and a key protein associated with paracellular permeability, which is impaired in autoimmune diseases. It is testing an antagonist of that protein as a therapy for celiac disease and eventually, type 1 diabetes.
You may also be interested in...
Intense interest in new diabetes drugs gives start-ups many choices for technology development or in-licensing, but recent regulatory caution also increases risk.
A new publication offers up proof of concept that the genetic signatures of microorganisms found in blood and tumor tissue could improve precision medicine cancer diagnostics. The study also bolsters the notion that targeting the microbiome could lead to innovative cancer therapies.
A better understanding of heme trafficking could lead to drug targets in metabolic diseases, anemias, porphyrias, hemolytic diseases such as sickle cell disease – even parasitic infections.